DNA methylation of GITR, OX40, 4-1BB, CD27 , and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved..
Uveal melanoma represents an aggressive tumor that responds mostly poorly to established melanoma treatments. Comprehensive methylation profiling of the next-generation immunotherapeutic target genes, for example, members of the tumor necrosis factor receptor superfamily, might allow for the development of companion predictive biomarkers. We have analyzed CpG sites within the immune checkpoint genes GITR, OX40, 4-1BB, CD 27, and CD40 probed by the Illumina Infinium HumanMethylation450 BeadChip in N = 80 uveal melanomas included in The Cancer Genome Atlas with regard to BAP1 aberrancy, mRNA expression, and overall survival. In all analyzed immune checkpoint genes, BAP1 aberrancy was associated with decreased CpG methylation levels. We identified specific CpG sites that significantly correlated with BAP1 aberrancy, mRNA expression levels, and overall survival. Our results suggest epigenetic regulation of the analyzed immune checkpoint genes via DNA methylation in uveal melanoma and provide rationale for methylation testing in biomarker programs in clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Melanoma research - 33(2023), 2 vom: 01. Apr., Seite 116-125 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hoffmann, Friederike [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.02.2023 Date Revised 01.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/CMR.0000000000000879 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352455020 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352455020 | ||
| 003 | DE-627 | ||
| 005 | 20231226053749.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CMR.0000000000000879 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352455020 | ||
| 035 | |a (NLM)36735464 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hoffmann, Friederike |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a DNA methylation of GITR, OX40, 4-1BB, CD27 , and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2023 | ||
| 500 | |a Date Revised 01.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a Uveal melanoma represents an aggressive tumor that responds mostly poorly to established melanoma treatments. Comprehensive methylation profiling of the next-generation immunotherapeutic target genes, for example, members of the tumor necrosis factor receptor superfamily, might allow for the development of companion predictive biomarkers. We have analyzed CpG sites within the immune checkpoint genes GITR, OX40, 4-1BB, CD 27, and CD40 probed by the Illumina Infinium HumanMethylation450 BeadChip in N = 80 uveal melanomas included in The Cancer Genome Atlas with regard to BAP1 aberrancy, mRNA expression, and overall survival. In all analyzed immune checkpoint genes, BAP1 aberrancy was associated with decreased CpG methylation levels. We identified specific CpG sites that significantly correlated with BAP1 aberrancy, mRNA expression levels, and overall survival. Our results suggest epigenetic regulation of the analyzed immune checkpoint genes via DNA methylation in uveal melanoma and provide rationale for methylation testing in biomarker programs in clinical trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a BAP1 protein, human |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Proteins |2 NLM | |
| 650 | 7 | |a Ubiquitin Thiolesterase |2 NLM | |
| 650 | 7 | |a EC 3.4.19.12 |2 NLM | |
| 650 | 7 | |a TNFRSF18 protein, human |2 NLM | |
| 650 | 7 | |a TNFRSF4 protein, human |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Receptor Superfamily, Member 7 |2 NLM | |
| 650 | 7 | |a CD40 Antigens |2 NLM | |
| 650 | 7 | |a TNFRSF9 protein, human |2 NLM | |
| 700 | 1 | |a Fröhlich, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Sirokay, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a de Vos, Luka |e verfasserin |4 aut | |
| 700 | 1 | |a Zarbl, Romina |e verfasserin |4 aut | |
| 700 | 1 | |a Dietrich, Jörn |e verfasserin |4 aut | |
| 700 | 1 | |a Strieth, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Landsberg, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Dietrich, Dimo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Melanoma research |d 1997 |g 33(2023), 2 vom: 01. Apr., Seite 116-125 |w (DE-627)NLM012645702 |x 1473-5636 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:2 |g day:01 |g month:04 |g pages:116-125 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/CMR.0000000000000879 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 2 |b 01 |c 04 |h 116-125 | ||